Buxhofer-Ausch V, et al. - Retrospective analysis of a large anagrelide registry in thrombocythemic MPN patients revealed a significantly greater risk of thrombosis attributed to elevated platelet (PLT) and white blood cell (WBC) counts, so researchers assessed the influence of elevated WBC counts on thrombosis risk in patients where anagrelide treatment reduced PLT counts below the calculated cutoff of 574.5 G/L. They applied Cox regression analysis and Kaplan-Meier plot on all patients in the registry with optimized PLT counts. According to the findings of this first investigation in a prospectively observed large patient cohort which was treated homogenously allowing for evaluation of single parameters for an effect on thrombophilia, attainment of a reduced thrombotic risk requires additional correction of elevated WBC counts in patients with optimally managed PLT counts.